Sirolimus as Secondary Therapy in Treating Patients With Chronic Graft-Versus-Host Disease That Did Not Respond to Previous Systemic Treatment - Related Studies

Sirolimus as Secondary Therapy in Treating Patients With Chronic Graft-Versus-Host Disease That Did Not Respond to Previous Systemic Treatment

This study is ongoing, but not recruiting participants.

Study NCT00079183. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Graft Versus Host Disease

2	Additional conditions recognized in this trial
		Graft vs Host Disease

3	More general conditions related to this trial
		Immune System Diseases

4	Interventions listed in this trial
		cyclosporine
		prednisone
		sirolimus
		tacrolimus

5	Additional drug interventions recognized in this trial
		Cyclosporins

6	More general drug interventions related to this trial
		Anti-Bacterial Agents
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Antibiotics, Antineoplastic
		Antifungal Agents
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Antirheumatic Agents
		Dermatologic Agents
		Enzyme Inhibitors
		Glucocorticoids
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Fred Hutchinson Cancer Research Center
		National Cancer Institute (NCI)